Wang X, Wu K, Zhang H, Liu J, Yang Z, Bai J
Biotechnol Lett. 2022; 44(11):1287-1299.
PMID: 36076042
DOI: 10.1007/s10529-022-03290-7.
Li T, Li L, Du F, Sun L, Shi J, Long M
Molecules. 2021; 26(11).
PMID: 34198909
PMC: 8201221.
DOI: 10.3390/molecules26113438.
Huttel W
Appl Microbiol Biotechnol. 2020; 105(1):55-66.
PMID: 33270153
PMC: 7778625.
DOI: 10.1007/s00253-020-11022-y.
Buda De Cesare G, Cristy S, Garsin D, Lorenz M
mBio. 2020; 11(6).
PMID: 33144376
PMC: 7642678.
DOI: 10.1128/mBio.02123-20.
Shivakumar M, Manohar S, Ishwar B, Raghu P, Savitha J
3 Biotech. 2019; 9(11):412.
PMID: 31696017
PMC: 6811456.
DOI: 10.1007/s13205-019-1946-7.
Efficient bioconversion of echinocandin B to its nucleus by overexpression of deacylase genes in different host strains.
Shao L, Li J, Liu A, Chang Q, Lin H, Chen D
Appl Environ Microbiol. 2012; 79(4):1126-33.
PMID: 23220968
PMC: 3568618.
DOI: 10.1128/AEM.02792-12.
Antifungal peptides: novel therapeutic compounds against emerging pathogens.
De Lucca A, Walsh T
Antimicrob Agents Chemother. 1998; 43(1):1-11.
PMID: 9869556
PMC: 89011.
DOI: 10.1128/AAC.43.1.1.
Antifungal agents: chemotherapeutic targets and immunologic strategies.
Georgopapadakou N, Walsh T
Antimicrob Agents Chemother. 1996; 40(2):279-91.
PMID: 8834867
PMC: 163103.
DOI: 10.1128/AAC.40.2.279.
Use of cilofungin as direct fluorescent probe for monitoring antifungal drug-membrane interaction.
Ko Y, Ludescher R, Frost D, Wasserman B
Antimicrob Agents Chemother. 1994; 38(6):1378-85.
PMID: 8092841
PMC: 188214.
DOI: 10.1128/AAC.38.6.1378.
Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis.
KURTZ M, Douglas C, Marrinan J, Nollstadt K, Onishi J, Dreikorn S
Antimicrob Agents Chemother. 1994; 38(12):2750-7.
PMID: 7695257
PMC: 188280.
DOI: 10.1128/AAC.38.12.2750.
Use of Saccharomyces cerevisiae expressing beta-galactosidase to screen for antimycotic agents directed against yeast cell wall biosynthesis and possible application to pathogenic fungi.
Zaworski P, Gill G
Antimicrob Agents Chemother. 1990; 34(4):660-2.
PMID: 2111659
PMC: 171662.
DOI: 10.1128/AAC.34.4.660.
Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis.
Walsh T, Lee J, Kelly P, Bacher J, Lecciones J, Thomas V
Antimicrob Agents Chemother. 1991; 35(7):1321-8.
PMID: 1929288
PMC: 245165.
DOI: 10.1128/AAC.35.7.1321.
Isolation and characterization of Saccharomyces cerevisiae mutants resistant to aculeacin A.
Font de Mora J, Gil R, Sentandreu R, Herrero E
Antimicrob Agents Chemother. 1991; 35(12):2596-601.
PMID: 1839761
PMC: 245437.
DOI: 10.1128/AAC.35.12.2596.
In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin.
Bartizal K, Abruzzo G, Trainor C, Krupa D, Nollstadt K, Schmatz D
Antimicrob Agents Chemother. 1992; 36(8):1648-57.
PMID: 1416847
PMC: 192025.
DOI: 10.1128/AAC.36.8.1648.
Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.
Lyman C, Walsh T
Drugs. 1992; 44(1):9-35.
PMID: 1379913
DOI: 10.2165/00003495-199244010-00002.
